Claimant scorecard · AERS v2.1 · Calibrating
OpenAI and Novo Nordisk
1 claim tracked in the Responsibility Ledger. 1 pending grade.
AERS
—
Insufficient closed grades
Pending
1
Open horizons
Closed
0
Graded outcomes
First tracked
Jun 11, 2026
Open horizons
OpenAI and Novo Nordisk: Announced strategic partnership April 14, 2026 to integrate AI across drug discovery, manufacturing, and commercial operations with full deployment by end of 2026
Invalidator — If by March 31, 2027, Novo Nordisk's Q4 2026 and Q1 2027 earnings calls contain no mention of operational AI deployment, no quantified improvements in research or manufacturing timelines, and no pipeline candidates attributed to OpenAI-powered discovery, the partnership will have remained a pilot program and the grade falls to C or lower.
About this scorecard
The AI Execution Risk Score (AERS) is a 0-100 metric quantifying the gap between OpenAI and Novo Nordisk’s public AI claims and demonstrated delivery. Higher AERS = stronger track record. Each claim above is drawn from a primary source linked in the original Ledger entry; the horizon date is when the claim becomes graded under the published methodology. Materiality is the editor’s assessment of the claim’s formality from 1 (PR statement) to 5 (earnings call or SEC filing).
AERS v2.1 · Methodology in active calibration · Not investment advice.